SCHEMBL17456007

SCHEMBL17456007

O=S(=O)(c1ccccc1)N1CCC(Oc2cccnc2-c2ccncc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.47
▸ NAMPT P43490 1/20 0.44
▸ SMN1; SMN2 Q16637 3/20 0.44
▸ NPC1 O15118 1/20 0.44
▸ RAB9A P51151 1/20 0.44
▸ HTR2B P41595 2/20 0.43
▸ IKBKB O14920 1/20 0.42
▸ CHUK O15111 1/20 0.42
▸ CYP3A4 P08684 2/20 0.42
▸ CYP2C9 P11712 2/20 0.42
▸ CYP1A2 P05177 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ HIF1A Q16665 1/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ PTGDR Q13258 2/20 0.42
▸ LSS P48449 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ CYP11B1 P15538 1/20 0.42
▸ CYP11B2 P19099 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17455979 0.94 MCHR1 (0.43) TDP1NAMPTSMN1; SMN2NPC1RAB9A
SCHEMBL17456043 0.89 SMN1; SMN2 (0.60) SMN1; SMN2NPC1RAB9ACYP2D6CYP2C19
SCHEMBL17455952 0.85 KDM4E (0.47) KDM4EMAPTHTR2CKCNH2
SCHEMBL17456044 0.85 MCHR1 (0.44) NAMPTRAB9AHTR2BKDM4ELSS
SCHEMBL17456004 0.83 SMN1; SMN2 (0.52) SMN1; SMN2NPC1RAB9ACYP2D6CYP2C19
SCHEMBL17455933 0.81 CYP11B1 (0.38) NAMPTIKBKBCHUKCYP3A4CYP11B1
SCHEMBL17455941 0.80 MCHR1 (0.41) TDP1NAMPTSMN1; SMN2NPC1RAB9A
SCHEMBL17456033 0.80 IKBKB (0.47) NAMPTIKBKBCHUKKDM4EMAPT
SCHEMBL17455945 0.80 CHRM1 (0.43) IKBKBCHUKHTR2AHTR2CKCNH2
SCHEMBL17455936 0.78 CACNB4 (0.39) NAMPTIKBKBCHUKCYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2982666-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-08-07 — — EP disclosed
EP-2982666-B1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICALS CO (JP) 2019-08-07 — — EP disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
US-9598398-B2 Heterocyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2017-03-21 — — US disclosed
EP-2982666-A1 HETEROCYCLIC COMPOUND Takeda Pharmaceutical Company Limited (JP) 2016-02-10 — — EP disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed
US-20160024049-A1 HETEROCYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2016-01-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160024049-A1 HETEROCYCLIC COMPOUND PSEN1, PSEN2, BACE1 TDP1 1024/4885NAMPT 367/4885SMN1; SMN2 23/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback